How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q4 Results?

Key Takeaways Eli Lilly's Mounjaro and Zepbound generated $24.8 billion in nine months, making up 54% of total revenues.Improved supply and new international launches are fueling strong sales momentum for both drugs.Lilly's oncology, immunology and neuroscience drugs also continue to support top-line expansion.Eli Lilly (LLY) has emerged as a dominant force in the cardiometabolic market, driven by strong demand for its blockbuster GLP-1 therapies, Mounjaro for type II diabetes (T2D) and Zepbound for obesity ...